Skip to main content
. 2023 Mar 8;9(10):eadc9436. doi: 10.1126/sciadv.adc9436

Fig. 5. Combination of CXCL16 and CCL20 synergizes to promote antitumor immunity.

Fig. 5.

(A) Schematic overview of the approach to recruit DCs to tumors via CCL20 production in probiotic bacteria to complement activated T cell recruitment via CXCL16 (as in Fig. 1A). (B) Tumor growth curves from C57BL/6 mice (n = 5 per group) subcutaneously implanted with 5 × 105 MC38 colorectal tumor cells on both hind flanks. When tumor volumes were 50 to 150 mm3, mice received intratumoral injections (indicated by black arrows) every 3 to 4 days with PBS, eSLC, eSLC-hCXCL16K42A, eSLC-CCL20, or eSLC-combo (1:1 mixture of eSLC-hCXCL16K42A and eSLC-CCL20). Data are representative of four independent experiments (***P < 0.001 and ****P < 0.0001, two-way ANOVA with Holm-Sidak post hoc test at the final measurement time point). (C to E) Flow cytometric analysis of tumor-infiltrating immune cells isolated from subcutaneously growing MC38 tumors (n ≥ 4 mice per group) following intratumoral injections [performed as in (B)] with PBS, eSLC, eSLC-hCXCL16K42A, or eSLC-combo [as in (A)]. (C) Frequencies and (D) numbers of cDC1s on day 5 after treatment. (E) Frequencies of intratumoral Granzyme-B+ CD8+ T cells. Data are representative of three independent experiments (*P < 0.05, one-way ANOVA with Holm-Sidak post hoc test). All data are displayed as means ± SEM.